Fulgent Genetics Stock Performance
| FLGT Stock | USD 17.09 0.20 1.18% |
The firm shows a Beta (market volatility) of 0.87, which means possible diversification benefits within a given portfolio. Fulgent Genetics returns are very sensitive to returns on the market. As the market goes up or down, Fulgent Genetics is expected to follow. At this point, Fulgent Genetics has a negative expected return of -0.1%. Please make sure to confirm Fulgent Genetics' value at risk, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Fulgent Genetics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Fulgent Genetics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's technical and fundamental indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 1.18 | Five Day Return (0.35) | Year To Date Return (7.22) | Ten Year Return 86.17 | All Time Return 86.17 |
1 | Disposition of 4733 shares by Jian Xie of Fulgent Genetics at 17.21 subject to Rule 16b-3 | 01/24/2025 |
2 | Disposition of tradable shares by Gao Hanlin of Fulgent Genetics at 17.0 subject to Rule 16b-3 | 01/30/2025 |
3 | Disposition of 1472 shares by Ming Hsieh of Fulgent Genetics at 16.64 subject to Rule 16b-3 | 01/31/2025 |
4 | Fulgent Genetics stock hits 52-week low at 16.32 - MSN | 02/03/2025 |
5 | Disposition of 733 shares by Paul Kim of Fulgent Genetics at 16.46 subject to Rule 16b-3 | 02/21/2025 |
6 | Acquisition by Ming Hsieh of 11280 shares of Fulgent Genetics subject to Rule 16b-3 | 02/25/2025 |
7 | Disposition of 11773 shares by Ming Hsieh of Fulgent Genetics at 16.24 subject to Rule 16b-3 | 02/26/2025 |
8 | Disposition of 2523 shares by Gao Hanlin of Fulgent Genetics at 16.24 subject to Rule 16b-3 | 02/27/2025 |
9 | Fulgent Genetics Inc Q4 2024 Earnings EPS Loss of Beats Estimate, Revenue at 76. ... | 02/28/2025 |
10 | Fulgent Sun International Is Due To Pay A Dividend Of NT2.00 | 03/04/2025 |
11 | Insider Buying Paul Kim Acquires 100,000 Shares of Fulgent Genetics Inc | 03/06/2025 |
12 | Disposition of 4344 shares by Jian Xie of Fulgent Genetics at 20.1 subject to Rule 16b-3 | 03/07/2025 |
13 | Proficio Capital Partners LLC Acquires Shares of 22,238 Fulgent Genetics, Inc. - MarketBeat | 03/14/2025 |
14 | Disposition of 1636 shares by Gao Hanlin of Fulgent Genetics at 16.29 subject to Rule 16b-3 | 03/17/2025 |
15 | Technical Pivots with Risk Controls - Stock Traders Daily | 03/20/2025 |
| Begin Period Cash Flow | 79.5 M |
Fulgent |
Fulgent Genetics Relative Risk vs. Return Landscape
If you would invest 1,859 in Fulgent Genetics on December 21, 2024 and sell it today you would lose (150.00) from holding Fulgent Genetics or give up 8.07% of portfolio value over 90 days. Fulgent Genetics is currently does not generate positive expected returns and assumes 2.6879% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Fulgent, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fulgent Genetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fulgent Genetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fulgent Genetics, and traders can use it to determine the average amount a Fulgent Genetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0389
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FLGT |
Estimated Market Risk
| 2.69 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Fulgent Genetics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fulgent Genetics by adding Fulgent Genetics to a well-diversified portfolio.
Fulgent Genetics Fundamentals Growth
Fulgent Stock prices reflect investors' perceptions of the future prospects and financial health of Fulgent Genetics, and Fulgent Genetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fulgent Stock performance.
| Return On Equity | -0.0387 | ||||
| Return On Asset | -0.0376 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | (0.21) % | ||||
| Current Valuation | 271.07 M | ||||
| Shares Outstanding | 30.83 M | ||||
| Price To Earning | 3.95 X | ||||
| Price To Book | 0.46 X | ||||
| Price To Sales | 1.84 X | ||||
| Revenue | 283.47 M | ||||
| Gross Profit | 107.22 M | ||||
| EBITDA | (73.92 M) | ||||
| Net Income | (43.82 M) | ||||
| Cash And Equivalents | 515.4 M | ||||
| Cash Per Share | 17.03 X | ||||
| Total Debt | 412 K | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 5.29 X | ||||
| Book Value Per Share | 36.74 X | ||||
| Cash Flow From Operations | 21.06 M | ||||
| Earnings Per Share | (1.41) X | ||||
| Market Capitalization | 520.71 M | ||||
| Total Asset | 1.22 B | ||||
| Retained Earnings | 590.47 M | ||||
| Working Capital | 280.67 M | ||||
| Current Asset | 2.93 M | ||||
| Current Liabilities | 686 K | ||||
About Fulgent Genetics Performance
Assessing Fulgent Genetics' fundamental ratios provides investors with valuable insights into Fulgent Genetics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Fulgent Genetics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 7.13 | 6.77 | |
| Return On Tangible Assets | (0.04) | (0.04) | |
| Return On Capital Employed | (0.06) | (0.07) | |
| Return On Assets | (0.04) | (0.04) | |
| Return On Equity | (0.04) | (0.04) |
Things to note about Fulgent Genetics performance evaluation
Checking the ongoing alerts about Fulgent Genetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fulgent Genetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fulgent Genetics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 283.47 M. Net Loss for the year was (43.82 M) with profit before overhead, payroll, taxes, and interest of 107.22 M. | |
| About 57.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Technical Pivots with Risk Controls - Stock Traders Daily |
- Analyzing Fulgent Genetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fulgent Genetics' stock is overvalued or undervalued compared to its peers.
- Examining Fulgent Genetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fulgent Genetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fulgent Genetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fulgent Genetics' stock. These opinions can provide insight into Fulgent Genetics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.